To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis

    Not Recruiting
  • participants needed
  • sponsor
    Ferring Pharmaceuticals
Updated on 18 June 2021
Clinical Development Support
Primary Contact
Ferring Investigator Site JPN43 (0.0 mi away) Contact
+71 other location


To demonstrate non-inferiority in efficacy of FE 999315 to mesalazine in patients with mild to moderate active ulcerative colitis after 8 weeks of treatment.

Condition Ulcerative Colitis, Ulcerative Colitis (Pediatric)
Treatment FE 999315 (6 mg), FE 999315 (9 mg), Mesalazine (3,600 mg), Budesonide (6 mg), Budesonide (9 mg)
Clinical Study IdentifierNCT03412682
SponsorFerring Pharmaceuticals
Last Modified on18 June 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note